open access
Vol 94, No 1 (2023)
Other materials agreed with the Editors
Published online: 2023-01-31
Get Citation
Molecular classification in endometrial cancer — are we ready?
1, 1
Affiliations- Department of Gynecologic Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
open access
Vol 94, No 1 (2023)
EDITORIAL
Published online: 2023-01-31
Abstract
Not available
Abstract
Not available
Get Citation
About this articleTitle
Molecular classification in endometrial cancer — are we ready?
Journal
Issue
Article type
Other materials agreed with the Editors
Pages
1-2
Published online
2023-01-31
Page views
3065
Article views/downloads
406
DOI
Pubmed
Bibliographic record
Ginekol Pol 2023;94(1):1-2.
Authors
Agnieszka Rychlik
Mariusz Bidzinski
References (16)- Kandoth C, Schultz N, Cherniack AD, et al. Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497(7447): 67–73.
- Talhouk A, Hoang LN, McConechy MK, et al. Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment. Gynecol Oncol. 2016; 143(1): 46–53.
- Talhouk A, McConechy MK, Leung S, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015; 113(2): 299–310.
- Talhouk A, McConechy MK, Leung S, et al. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017; 123(5): 802–813.
- Stelloo E, Bosse T, Nout RA, et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod Pathol. 2015; 28(6): 836–844.
- Bayramoglu D, Seçilmiş Kerimoğlu Ö, Bayramoğlu Z, et al. Classification of high-grade endometrium carcinomas using molecular and immunohistochemical methods. Ginekol Pol. 2022 [Epub ahead of print].
- Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021; 31(1): 12–39.
- Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020; 38(1): 1–10.
- Oaknin A, Tinker A, Gilbert L, et al. Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer. JAMA Oncology. 2020; 6(11): 1766.
- Fader AN, Roque DM, Siegel E, et al. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. J Clin Oncol. 2018; 36(20): 2044–2051.
- Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program. International Journal of Gynecologic Cancer. 2022; 33(1): 109–117.
- van den Heerik AS, Horeweg N, Nout RA, et al. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. Int J Gynecol Cancer. 2020; 30(12): 2002–2007.
- León-Castillo A, de Boer SM, Powell ME, et al. TransPORTEC consortium. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. J Clin Oncol. 2020; 38(29): 3388–3397.
- Bartosch C, Clarke B, Bosse T. Gynaecological neoplasms in common familial syndromes (Lynch and HBOC). Pathology. 2018; 50(2): 222–237.
- Mur P, García-Mulero S, Del Valle J, et al. Role of POLE and POLD1 in familial cancer. Genet Med. 2020; 22(12): 2089–2100.
- Bidzinski M, Danska-Bidzinska A, Rychlik A, et al. Molecular classification of endometrial carcinoma, is it the new era of precision medicine? Ginekologia Polska. 2022; 93(2): 163–167.
